Genetown
Filter News
Found 92,326 articles
-
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
3/18/2024
Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant.
-
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
3/18/2024
Checkpoint Therapeutics, Inc. today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.
-
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
3/18/2024
Orchard Therapeutics announced the U.S. Food and Drug Administration has approved Lenmeldy™, formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile —collectively referred to as early-onset—metachromatic leukodystrophy.
-
Spyre Therapeutics Announces $180 Million Private Placement - March 18, 2024
3/18/2024
Spyre Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses.
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
3/18/2024
Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
-
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
3/18/2024
Verastem Oncology announced new results from the first-ever global LGSOC Patient Impact Survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer.
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3/18/2024
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc.
-
Maplight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
3/18/2024
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.
-
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
3/18/2024
Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, announced its partner, DEKA Research & Development Corp., has received 510 clearance from the U.S. Food and Drug Administration for the innovative twiist™ Automated Insulin Delivery system powered by Tidepool.
-
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
3/18/2024
Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the fourth quarter and year ended December 31, 2023.
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
3/18/2024
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
3/18/2024
Fulcrum Therapeutics, Inc.® announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately.
-
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
3/18/2024
GRO Biosciences Inc., an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, announced the expansion of its leadership with the hire of Tracey Lodie, PhD as Chief Development Officer.
-
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
3/18/2024
Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
3/18/2024
BiomX Inc. announced the closing of its previously announced acquisition of Adaptive Phage Therapeutics, Inc. and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.
-
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
3/18/2024
Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.
-
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
3/18/2024
T2 Biosystems, Inc. today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology.
-
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
3/18/2024
Faron Pharmaceuticals Ltd. today provided further data from patients treated during the Phase 1 part of the ongoing BEXMAB trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients failed on previous hypomethylating agent (HMA).